Last reviewed · How we verify
NB003
At a glance
| Generic name | NB003 |
|---|---|
| Sponsor | Ningbo Newbay Technology Development Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Multicenter, Open-label Clinical Study to Evaluate the Efficacy and Safety of NB003 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) (PHASE2, PHASE3)
- A Study of NB003 in Patients With Advanced Malignancies (PHASE1)
- First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NB003 CI brief — competitive landscape report
- NB003 updates RSS · CI watch RSS
- Ningbo Newbay Technology Development Co., Ltd portfolio CI